“Ayushman has deep expertise in advising life sciences clients on commercial, clinical, medical, and manufacturing strategy in the gene therapy, rare disease, and oncology spaces,” said Paul Maleh, CRA’s Chairman and Chief Executive Officer. “I am pleased to welcome him to CRA, where he is joining a team that has long been recognized for its ability to provide clarity and solutions for the industry’s most complex issues.”
“Ayushman has the perspective of both an industry veteran and an experienced consultant, which is an invaluable asset in working with life sciences companies, particularly in helping them to develop and implement commercialization and product launch strategies,” said Dr. Gregory K. Bell, Group Vice President and Life Sciences Practice Leader.
Prior to joining CRA, Ghosh led several practice areas, key partnerships, and biotech investments as a senior vice president for a life sciences-focused boutique consulting firm. He led a team of more than 20 consultants across major accounts and alliance partnerships with a focus on gene therapy, rare disease, and oncology. Previously, he drove commercial, market access, and corporate strategy engagements at a management consulting firm specializing in the biopharmaceutical industry. He started his career as a scientist at a large, multinational pharmaceutical company where he focused on process optimization and commercialization of novel biologics. Ghosh has a MS in Chemical Engineering from Columbia University and a BS in Chemical Biological Engineering from the Massachusetts Institute of Technology.